- Published: Wednesday March 29 2017 11: 51
The young Nosopharm pharmaceutical company said Tuesday it has raised € 2,4 million to help it develop a new class of antibiotics.
This amount was paid by investment companies Auriga Partners Kreaxi and Alto Invest "joining the historic shareholders of the company," according to a statement.
The funds raised will enable Nosopharm accelerate the preclinical development of its first antibiotic molecule NOSO-95179, which targets Enterobacteriaceae, a specific priority pathogens by WHO.
The first clinical trials in humans should start running 2019, adds the company.
Founded in Nîmes (Gard), Nosopharm comes from a collaboration with the National Institute for Agricultural Research (INRA).